Intensity Therapeutics Inc. (INTS)
NASDAQ (CM) NASDAQ (CM) Primary 
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Intensity Therapeutics Inc. (INTS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to Buy
Intensity Therapeutics Inc. (INTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology Transcript
Intensity Therapeutics, Inc. ( INTS ) Discusses eBioMedicine Paper Study Results and Underlying Technology October 31, 2025 9:00 AM EDT Company Participants Lewis Bender - Founder, President, CEO & Chairman of the Board Conference Call Participants Jacob Stephen Thomas Anthony El-Khoueiry Kumaraguru Raja - Brookline Capital Markets, LLC, Research Division Presentation Operator Welcome to the Intensity Therapeutics Discovery Lancet Discovery Group eBioMedicine Publication Webinar. [Operator Instructions] Please also note today's event is being recorded.
